Biosensors' proprietary BA9™ drug specifically designed for stent use, is coated on the following stents:
Bridging science and innovative technology
In the early 2000's the available mTOR inhibitor limus drugs, available for coronary stenting, were developed for systemic application. Biosensors developed its own proprietary limus technology by focusing during the early stages of drug development on its use for vascular technologies.
BA9™ Designed for Vascular Stent Technologies, optimized for local drug delivery
The Research and Development team developed several versions of Biolimus, through a number of iterations ultimately decided to focus on BA9™ (Biolimus A9™), as the best option for coronary stent application. Consequently, Biosensors' proprietary limus drug BA9™ was used within its BioMatrix™ DES family and BioFreedom™ DCS.
BA9™ key characteristics. 10 times more lipophilic than Sirolimus1
- Slower metabolism of drug due to its structure
- High local bioavailability2
- Long 20-day in tissue half-life2